MT-2004 is under clinical development by Shaanxi Micot Technology and currently in Phase II for Cholestasis. According to GlobalData, Phase II drugs for Cholestasis have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MT-2004’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MT-2004 overview

MT-2004 is under development for the treatment of non-chronic liver diseases such as nonalcoholic fatty liver disease, non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis, acute cholestatic and mixed drug-induced liver injury and portal hypertension. It is administered through oral route. It acts by targeting farnesoid X receptor (FXR). 

Shaanxi Micot Technology overview

Shaanxi Micot Technology Co. Ltd., is a pharmaceutical company that develops polypeptide drugs. The company is headquartered in Xi’an, Shaanxi, China.

For a complete picture of MT-2004’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.